UBS Asset Management Americas Inc. increased its position in Core Laboratories NV (NYSE:CLB) by 7.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 113,549 shares of the company’s stock after buying an additional 8,283 shares during the period. UBS Asset Management Americas Inc. owned about 0.26% of Core Laboratories NV worth $14,068,000 as of its most recent filing with the SEC.
Other hedge funds also recently modified their holdings of the company. MU Investments Co. Ltd. bought a new stake in shares of Core Laboratories NV during the second quarter worth approximately $115,000. CIBC World Markets Inc. bought a new stake in shares of Core Laboratories NV during the second quarter worth approximately $205,000. Dynamic Advisors Solutions LLC bought a new stake in shares of Core Laboratories NV during the first quarter worth approximately $214,000. Creative Planning boosted its stake in shares of Core Laboratories NV by 19.8% in the second quarter. Creative Planning now owns 1,814 shares of the company’s stock worth $225,000 after buying an additional 300 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Core Laboratories NV during the first quarter worth approximately $233,000.
Core Laboratories NV (NYSE:CLB) traded down 2.75% during midday trading on Friday, hitting $104.85. The stock had a trading volume of 398,257 shares. The firm has a market capitalization of $4.62 billion, a P/E ratio of 55.62 and a beta of 1.56. Core Laboratories NV has a 52-week low of $84.50 and a 52-week high of $135.49. The firm has a 50-day moving average of $113.50 and a 200 day moving average of $117.85.
Core Laboratories NV (NYSE:CLB) last issued its earnings results on Wednesday, July 20th. The company reported $0.35 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.35. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. The firm earned $148.10 million during the quarter, compared to analysts’ expectations of $146.37 million. During the same quarter last year, the company posted $0.81 earnings per share. The firm’s revenue was down 27.4% compared to the same quarter last year. On average, equities analysts forecast that Core Laboratories NV will post $1.57 EPS for the current year.
A number of analysts have recently commented on the company. JPMorgan Chase & Co. reissued a “buy” rating on shares of Core Laboratories NV in a research report on Thursday, June 30th. KLR Group reissued a “buy” rating and issued a $180.00 price target (up from $166.00) on shares of Core Laboratories NV in a research report on Monday, June 13th. Citigroup Inc. dropped their price target on Core Laboratories NV from $123.00 to $118.00 and set a “neutral” rating on the stock in a research report on Monday, July 25th. Zacks Investment Research raised Core Laboratories NV from a “hold” rating to a “buy” rating and set a $138.00 price objective on the stock in a research report on Wednesday, July 20th. Finally, Credit Suisse Group AG initiated coverage on Core Laboratories NV in a research report on Thursday, September 1st. They issued a “neutral” rating and a $115.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $120.12.
Core Laboratories NV Company Profile
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.